Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 4/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7870100 | 0.94 | CPS1 (0.59) | CPS1EPHX2MEN1KMT2ALMNA | |
| SCHEMBL18311852 | 0.91 | MEN1 (0.59) | CPS1EPHX2MEN1KMT2ALMNA | |
| SCHEMBL7872416 | 0.88 | CPS1 (0.57) | CPS1EPHX2MEN1KMT2ALMNA | |
| SCHEMBL7878686 | 0.87 | CPS1 (0.60) | CPS1LMNATSHRHTTMAPT | |
| SCHEMBL13841322 | 0.86 | KDM4E (0.63) | CPS1EPHX2MEN1KMT2ALMNA | |
| SCHEMBL12205464 | 0.86 | CPS1 (0.58) | CPS1MEN1KMT2ALMNATSHR | |
| SCHEMBL7871464 | 0.84 | HTT (0.53) | CPS1MEN1KMT2ALMNATSHR | |
| SCHEMBL11961209 | 0.84 | HRH4 (0.54) | MEN1KMT2ALMNATSHRHTT | |
| SCHEMBL13503857 | 0.84 | POLB (0.61) | MEN1KMT2ALMNATSHRHTT | |
| SCHEMBL7870107 | 0.84 | CPS1 (0.54) | CPS1LMNATSHRHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-9840517-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-20160229865-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | CPS1 3443/4885EPHX2 1339/4885MEN1 4307/4885 |
| US-20160229865-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | BTK, JAK3, JAK2 | CPS1 4565/4885EPHX2 3693/4885MEN1 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.